Direct Answer
AbbVie is a biopharmaceutical company best known for Humira, once the world's best-selling drug, now facing biosimilar competition. The investment case hinges on whether Rinvoq and Skyrizi (the immunology successors) plus the Allergan aesthetics franchise (Botox, Juvederm) can replace lost Humira revenue. AbbVie was spun out of Abbott Laboratories in 2013 and has been a Dividend Aristocrat since becoming an independent company.
Company snapshot
| Field | Detail |
|---|---|
| Company | AbbVie Inc. |
| Ticker | ABBV |
| Exchange | NYSE |
| Index | S&P 500, Wilshire 5000 |
| Sector | Health Care |
| Industry | Biotechnology |
| Headquarters | North Chicago, Illinois, United States |
| Founded | 2013 (spun from Abbott Laboratories) |
| Fiscal year end | December 31 |
| SEC CIK | 0001551152 |
What AbbVie does
AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines in immunology, oncology, neuroscience, and aesthetics. The company was spun off from Abbott Laboratories in January 2013 and has grown through organic pipeline development and major acquisitions, most significantly the $63 billion acquisition of Allergan in May 2020.
AbbVie's key marketed products span four therapeutic areas:
- Immunology: Humira (adalimumab), approved for rheumatoid arthritis, Crohn's disease, plaque psoriasis, and other inflammatory conditions; Rinvoq (upadacitinib), a JAK1-selective inhibitor with approved indications across 11+ inflammatory diseases; Skyrizi (risankizumab), an IL-23 inhibitor for plaque psoriasis, Crohn's disease, and ulcerative colitis
- Oncology: Imbruvica (ibrutinib, co-developed with Janssen/J&J), a BTK inhibitor for chronic lymphocytic leukemia and other blood cancers; Venclexta (venetoclax, co-developed with Roche/Genentech), a BCL-2 inhibitor for CLL and acute myeloid leukemia
- Neuroscience: Vraylar (cariprazine) for schizophrenia, bipolar disorder, and major depressive disorder; Ubrelvy (ubrogepant) for migraine; Qulipta for migraine prevention; Botox Therapeutic for migraine, spasticity, and hyperhidrosis
- Aesthetics: Botox Cosmetic, Juvederm (hyaluronic acid fillers), Coolsculpting body contouring, SkinMedica skincare
The Humira biosimilar transition
Humira was the world's best-selling drug for over a decade, generating peak annual revenue exceeding $20 billion. AbbVie aggressively defended Humira's market exclusivity through a patent thicket covering the drug's formulation, manufacturing, and delivery devices, delaying U.S. biosimilar competition until January 2023 even though international biosimilars had launched years earlier.
Since 2023, Humira's U.S. revenue has declined as biosimilar versions from Amgen, Pfizer, and others have entered the market. AbbVie's counter-strategy has been threefold: offering deep rebates to payers to maintain Humira formulary position, accelerating the growth of Rinvoq and Skyrizi which have better clinical profiles in several indications (Rinvoq outperformed Humira in head-to-head trials for atopic dermatitis), and leveraging the Allergan aesthetics business as a non-pharmacy-benefit revenue stream that is not subject to the same biosimilar competition dynamics.
AbbVie has guided that the combined revenue of Rinvoq and Skyrizi will surpass Humira's 2023 revenue level by approximately 2025 to 2027, representing a successful succession if achieved.
Risks and watchlist
- Humira erosion rate: The pace of biosimilar market share capture affects how quickly AbbVie needs Rinvoq and Skyrizi to scale. Faster erosion reduces the revenue bridge.
- Rinvoq safety label: JAK inhibitors as a class carry boxed warnings for cardiovascular events, thrombosis, malignancy, and mortality. Label restrictions or new safety signals could limit Rinvoq's prescribing in some populations.
- Imbruvica competition: Next-generation BTK inhibitors (zanubrutinib, acalabrutinib) have shown advantages in certain blood cancer subpopulations, accelerating Imbruvica share loss.
- Drug pricing legislation: The Inflation Reduction Act's Medicare drug price negotiation provisions could affect AbbVie's high-revenue products. Imbruvica was among the first drugs selected for Medicare negotiation.
- Pipeline risk: Long-term revenue growth requires new drugs in the pipeline to succeed in development and gain approval; late-stage failures can be significant for expectations.
Frequently asked questions
What does AbbVie do?
AbbVie Inc. is a global biopharmaceutical company that discovers, develops, and commercializes medicines for immunology, oncology, neuroscience, and aesthetics. AbbVie was spun off from Abbott Laboratories in 2013 and is best known for Humira (adalimumab), the anti-inflammatory biologic that was the world's best-selling drug for over a decade. AbbVie's portfolio also includes Rinvoq (upadacitinib, a JAK inhibitor), Skyrizi (risankizumab, an IL-23 inhibitor), Imbruvica (ibrutinib, a BTK inhibitor for blood cancers, co-developed with Janssen), Venclexta (venetoclax, a BCL-2 inhibitor for blood cancers, co-developed with Roche), and the Allergan aesthetics portfolio (Botox, Juvederm, Coolsculpting), acquired in 2020 for approximately $63 billion.
How does AbbVie make money?
AbbVie generates revenue primarily from pharmaceutical product sales, with its largest revenue contributors being the immunology franchise (Humira, Rinvoq, Skyrizi), the oncology franchise (Imbruvica, Venclexta), the neuroscience portfolio (Vraylar, Botox Therapeutic), and the aesthetics segment (Botox Cosmetic, Juvederm injectable fillers). Historically, Humira alone represented more than half of AbbVie's total revenue. The biosimilar entry in the U.S. beginning in 2023 has been reducing Humira's revenue contribution, but AbbVie has strategically invested in Rinvoq and Skyrizi as the succession drugs intended to replace the lost Humira revenue over time.
What happened to AbbVie's Humira revenue when biosimilars launched?
Humira (adalimumab) had been the world's best-selling drug for over a decade, with U.S. patent protection that allowed AbbVie to charge premium prices with no biosimilar competition. When Humira's core compound patents expired and U.S. biosimilar versions launched in January 2023, AbbVie faced direct price and volume competition for the first time. AbbVie's strategy involved deep pricing concessions to retain share (offering rebates to payers that chose to keep Humira on formulary), while simultaneously investing to accelerate the adoption of Rinvoq and Skyrizi, which have broader approved indications and potentially better clinical profiles in several diseases. By 2024, the combined sales of Rinvoq and Skyrizi were growing rapidly enough to partially offset Humira's biosimilar erosion, and AbbVie provided guidance that the two drugs would together surpass Humira's peak revenue by 2025 to 2027.
Why did AbbVie acquire Allergan and what does the aesthetics business contribute?
AbbVie acquired Allergan in 2020 for approximately $63 billion, adding a portfolio of medical aesthetics products (Botox Cosmetic, Juvederm injectable fillers, Coolsculpting body contouring) and neurology/psychiatry drugs (Vraylar, Ubrelvy migraine treatment). The aesthetics business was strategically attractive because it operates on cash-pay economics: most cosmetic procedures are not covered by insurance, so AbbVie's revenue is less subject to the payer negotiation and formulary management pressures that affect prescription drug pricing. Botox Cosmetic and Juvederm are category-defining brands in medical aesthetics that benefit from physician familiarity, training investment, and consumer brand recognition. The Allergan acquisition also brought Botox Therapeutic (the prescription use for migraines, spasticity, and hyperhidrosis), which is covered by insurance and has a distinct growth profile from the cosmetic business.
What are the main risks for AbbVie investors to watch?
Key risks include Humira biosimilar revenue erosion (biosimilar competition has been reducing Humira's U.S. revenue contribution since 2023; the magnitude of ongoing erosion depends on payer formulary decisions and AbbVie's pricing strategy), Rinvoq/Skyrizi execution (the investment case requires these two drugs to grow fast enough to offset Humira losses and sustain the overall revenue base; clinical setbacks, label restrictions, or slower-than-expected uptake would be significant negatives), Imbruvica competitive pressure (next-generation BTK inhibitors including AbbVie's own Calquence have been competing with Imbruvica; ongoing Imbruvica revenue decline is factored in but accelerating competition adds risk), pipeline dependency (AbbVie's long-term revenue growth requires successful development and approval of new drugs to sustain the portfolio beyond Rinvoq, Skyrizi, and Venclexta), and drug pricing legislation (legislative actions targeting Medicare drug price negotiation, most-favored-nation pricing proposals, or international reference pricing could affect profitability of AbbVie's high-revenue products).